Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
Appointed director
Ocera Therapeutics, Inc. (OCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/11/2017 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Amended and Restated Certificate of Incorporation of Ocera Therapeutics, Inc",
"Amended and Restated Bylaws of Ocera Therapeutics, Inc"
11/02/2017 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...
Docs: "Agreement and Plan of Merger, by and among Ocera Therapeutics, Inc., MAK LLC, MEH Acquisition Co., and for limited purposes, Mallinckrodt plc",
"Amendment to Bylaws of the Company",
"Form of Tender and Support Agreement",
"MALLINCKRODT TO ACQUIRE OCERA THERAPEUTICS AND OCR-002, ITS PROPRIETARY THERAPY IN DEVELOPMENT FOR TREATMENT OF HEPATIC ENCEPHALOPATHY"
09/29/2017 8-K Quarterly results
08/04/2017 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
06/22/2017 8-K Form 8-K - Current report
05/09/2017 8-K Form 8-K - Current report
03/31/2017 8-K Form 8-K - Current report
03/10/2017 8-K Form 8-K - Current report
03/08/2017 8-K Form 8-K - Current report
01/30/2017 8-K Form 8-K - Current report
01/09/2017 8-K Form 8-K - Current report
12/07/2016 8-K Form 8-K - Current report
11/02/2016 8-K Form 8-K - Current report
10/28/2016 8-K Form 8-K - Current report
09/21/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure"
09/19/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Ocera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic Encephalopathy --Phase 2b STOP-HE Enrollment Surpasses 205 Patients; On Track to Complete in Q4 2016--"
09/15/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/03/2016 8-K Quarterly results
Docs: "Ocera Therapeutics Reports Second Quarter 2016 Financial Results and Company Update"
06/21/2016 8-K Regulation FD Disclosure
06/15/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Ocera Therapeutics, Inc. Fourth Amended and Restated 2011 Stock Option and Incentive Plan, together with forms of award agreements"
04/29/2016 8-K Form 8-K - Current report
03/03/2016 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Ocera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update -- Patient enrollment progressing in STOP-HE clinical trial of OCR-002; Company expects to complete enrollment in the fourth quarter of 2016 -- -- OCR-002 is the only ammonia scavenger in development for both treatment and prevention of hepatic encephalopathy --"
11/06/2013 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Warrant",
"Securities Purchase Agreement, by and among Ocera Therapeutics, Inc. and the Purchasers identified therein",
"Registration Rights Agreement, by and among Ocera Therapeutics, Inc. and the Purchasers identified therein",
"Ocera Therapeutics Announces $28 Million Private Placement Financing Led by New Investors Vivo Capital and Venrock"
10/16/2013 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
09/05/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement by and between Ocera Therapeutics, Inc. and Jeryl Lynn Hilleman",
"Ocera Therapeutics, Inc. Non-Employee Director Compensation Policy",
"Jeryl L. Hilleman Joins Ocera Therapeutics as Chief Financial Officer"
08/13/2013 8-K SEC Filing in the EDGAR database
Docs: "Update Your Browser",
"Update Your Browser"
05/09/2013 8-K Quarterly results
05/03/2013 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
04/24/2013 8-K Conference call transcript
Docs: "Transcript of conference call held on April 24, 2013"
03/13/2013 8-K Resignation/termination of a director
02/12/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Severance Agreement by and between Tranzyme, Inc. and David Moore",
"Retention and Change in Control Agreement by and between Tranzyme, Inc. and Rhonda L. Stanley"
01/03/2013 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
12/17/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results"
12/04/2012 8-K Termination of a Material Definitive Agreement
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy